All Stories

  1. Trends and determinants of childhood anxiety disorders burden in Asia, 1990–2023
  2. RNA methylation in cardiovascular remodeling: Molecular mechanisms, biomarkers, and therapeutic strategies
  3. Regional disparities and metabolic determinants of type 2 diabetes in women aged 55 and older
  4. Temporal patterns and predictive factors of depressive disorders among adolescents and young people in Asia
  5. The gut-brain axis in diabetic neuropathy, cognitive impairment, and emotional disorders
  6. STAT Signaling in Metabolic Disorders: From Molecular Mechanisms to Therapeutic Implications
  7. Epidemiological Trajectories and Quality of Care Disparities of MASLD in Asia, 1990–2023
  8. Global Trends and Projections in Chronic Kidney Disease Burden from Diabetes, Hypertension, and Glomerulonephritis: A Population-Based Study
  9. Microbiota-Targeted Modulation of the Gut–Kidney Axis in Diabetic Kidney Disease: Therapeutic Advances and Future Perspectives
  10. Temporal Patterns and Predictive Factors of Childhood Depressive Disorders Across Asia
  11. Sterol Regulatory Element-Binding Proteins and Metabolic Diseases: Mechanisms, Implications, and Therapeutic Strategies
  12. Association between cardiometabolic index and thyroid function: insights from NHANES
  13. The Role of Lactate Metabolism in Tumors
  14. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
  15. Autophagy–senescence interplay in kidney disease: mechanistic insights and therapeutic potential
  16. Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus
  17. Global burden of rheumatic vs non-rheumatic valvular heart disease, 1990–2021: a systematic analysis of the global burden of disease study
  18. Flavonoids in Metabolic Disease: A Narrative Review of Mechanisms and Therapeutic Potential
  19. Ribosome collisions and ZAKα activation: explores the therapeutic potential of metabolic diseases
  20. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study...
  21. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  22. METTL3-mediated m6A methylation: implications for diabetes pathogenesis and therapeutic potential
  23. The role and therapeutic potential of exosome-mediated microRNAs regulatory networks in diabetic kidney disease
  24. Editorial: Novel approaches to diet, exercise, and drugs in childhood obesity and metabolic diseases
  25. Efficacy and safety benefits of HR17031 , a fixed‐ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with ty...
  26. Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment
  27. Multimodal Neuroimaging of Brain Structure, Metabolism, and Function in Obesity: Current Landscape and Future Perspectives
  28. Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management
  29. Global epidemiology and burden of type 2 diabetes in adults aged 55 and older: insights from 1990 to 2021
  30. Aging-Related Obesity: Unveiling Mitochondrial and Metabolic Dysfunction
  31. The global, regional, and national burden and attributable risk factors of Alzheimer's disease and other dementias, 1990-2021: A systematic analysis for the Global Burden of Disease Study
  32. Global epidemiology of type 1 diabetes in youth: 1990–2021 and projections to 2045
  33. Therapeutic Potential of Ginsenosides in the Treatment of Endocrine Diseases: Roles and Mechanisms
  34. Epigenetic regulation of nuclear receptors: Implications for endocrine-related diseases and therapeutic strategies
  35. Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045
  36. Nutritional Influences on Brown and Beige Adipocyte: Unraveling the Molecular Mechanisms and Metabolic Implications
  37. Associations between visceral adipose index, lipid accumulation products, and thyroid function parameters in U.S. Adults: analysis of NHANES data
  38. Exploring the Therapeutic Role of Pregnane X Receptor Activation in Acute Kidney Injury: Mechanisms and Clinical Implications
  39. Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease: Unraveling Connections and Advancing Therapies
  40. Glycerophospholipid and Sphingosine- 1-phosphate Metabolism in Cardiovascular Disease: Mechanisms and Therapeutic Potential
  41. KRAS Mutations in Cancer
  42. Updated Insights on Childhood Diabetes Epidemiology 2019-2021 and Projections to 2045
  43. Revolutionizing public health through digital health technology
  44. Exploring heparin’s protective mechanism against AGEs induced endothelial injury
  45. Editorial: Metabolic diseases and healthy aging: prevention and public health policy based on risk factors
  46. The influence of perceived formative assessment on the learning autonomy of medical students: the chain mediating role of psychological empowerment and positive academic emotions
  47. Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation
  48. The complex link between the gut microbiome and obesity-associated metabolic disorders: Mechanisms and therapeutic opportunities
  49. Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice
  50. Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management
  51. Metagenomic and metabolomic analysis showing the adverse risk–benefit trade-off of the ketogenic diet
  52. Exploring the multi-targeting phytoestrogen potential of Calycosin for cancer treatment: A review
  53. The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy
  54. Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
  55. Epidemiology of 369 diseases and injuries attributable to 84 risk factors: 1990–2019 with 2040 projection
  56. Environmental toxicology of bisphenol A: Mechanistic insights and clinical implications on the neuroendocrine system
  57. 20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3‐mediated Wnt/β‑catenin signaling pathway
  58. Editorial: Potential pathophysiological mechanisms underlying the comorbidity of depression and macrovascular diseases
  59. Unraveling the role of the FHL family in cardiac diseases: Mechanisms, implications, and future directions
  60. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances
  61. Metabolic diseases and healthy aging: identifying environmental and behavioral risk factors and promoting public health
  62. BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
  63. Changing trends of the diseases burden attributable to high BMI in Asia from 1990 to 2019: results from the global burden of disease study 2019
  64. Secreted frizzled-related protein 5: A promising therapeutic target for metabolic diseases via regulation of Wnt signaling
  65. Secreted frizzled-related proteins: A promising therapeutic target for cancer therapy through Wnt signaling inhibition
  66. Role of dysfunctional peri-organ adipose tissue in metabolic disease
  67. Editorial: Incretin agonists in the treatment of obesity
  68. Mechanisms and efficacy of traditional Chinese herb monomers in diabetic kidney disease
  69. Global, Regional, and National Epidemiology of Diabetes in Children From 1990 to 2019
  70. Astrocytes in Post-Stroke Depression: Roles in Inflammation, Neurotransmission, and Neurotrophin Signaling
  71. Editorial: Clinical and genetic determinants of diabetes and complications
  72. Optimizing glycation control in diabetes: An integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules
  73. Editorial: The impact of adipose tissue dysfunction on cardiovascular and renal disease, Volume II
  74. Global, Regional, and National Burden of Pancreatic Cancer, 1990–2019: Results from the Global Burden of Disease Study 2019
  75. Editorial: Aging and chronic disease: public health challenge and education reform
  76. NTRK fusions in thyroid cancer: Pathology and clinical aspects
  77. Secular trends of epidemiologic patterns of chronic kidney disease over three decades: an updated analysis of the Global Burden of Disease Study 2019
  78. Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance (Review)
  79. Case report: Maturity-Onset Diabetes of the Young (MODY12) caused by ABCC8 gene mutations
  80. Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019
  81. Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice
  82. Identification of Potential Indicators for Survival in Patients with Thyroid Cancer Based on Expression of FAM3 Members
  83. Advances in Understanding the Roles of Mesenchymal Stem Cells in Lung Cancer
  84. Calycosin induces autophagy and apoptosis via Sestrin2/AMPK/mTOR in human papillary thyroid cancer cells
  85. Irisin protects against obesity-related chronic kidney disease by regulating perirenal adipose tissue function in obese mice
  86. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
  87. Glutaminolysis and CD4+ T-cell metabolism in autoimmunity: From pathogenesis to therapy prospects
  88. Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
  89. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
  90. COL1A1: A novel oncogenic gene and therapeutic target in malignancies
  91. The Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus
  92. Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis
  93. Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy
  94. Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development
  95. Utilizing Network Pharmacology and Molecular Docking Integrated Surface Plasmon Resonance Technology to Investigate the Potential Targets and Mechanisms of Tripterygium wilfordii against Pulmonary Artery Hypertension
  96. Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report
  97. Doctor of Public Health-Crisis Management and COVID-19 Prevention and Control: A Case Study in China
  98. Online Education Plight and Countermeasures for MBBS in Chinese Regional Medical Schools Based on the OBE Concept During COVID-19 Pandemic
  99. Editorial: The Impact of Adipose Tissue Dysfunction on Cardiovascular and Renal Disease
  100. Evodiamine induces ROS-Dependent cytotoxicity in human gastric cancer cells via TRPV1/Ca2+ pathway
  101. Comprehensive Analysis of Tumor Immune Microenvironment and Prognosis of m6A-Related lncRNAs in Lung Adenocarcinoma
  102. Association between serum Sestrin2 level and diabetic peripheral neuropathy in type 2 diabetic patients
  103. Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
  104. A paradoxical role for sestrin 2 protein in tumor suppression and tumorigenesis
  105. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
  106. Identification of tRNA-derived Fragments and Their Potential Roles in Atherosclerosis
  107. Comprehensive overview of human serum albumin glycation in diabetes mellitus
  108. DL‑3‑n‑butylphthalide protects H9c2 cardiomyoblasts from ischemia/reperfusion injury by regulating HSP70 expression via PI3K/AKT pathway activation
  109. The analgesic efficacy of extracorporeal shock wave combined with percutaneous vertebroplasty in the treatment of osteoporotic thoracolumbar compression fractures in postmenopausal women
  110. Growth differentiation factor 11: a “rejuvenation factor” involved in regulation of age-related diseases?
  111. How to recognize and respond to viral re-positivity and disease relapse in patients with COVID-19
  112. Relationship between serum Dickkopf-1 and albuminuria in patients with type 2 diabetes
  113. Attaching clinical significance to COVID-19-associated diarrhea
  114. Identification of Potential Indicators for Survival in Patients With Thyroid Cancer Based on Mrna Expression Levels of Family With Sequence Similarity 3 Members
  115. Liraglutide improves obesity‐induced renal injury by alleviating uncoupling of the glomerular VEGF–NO axis in obese mice
  116. Epidemiology and clinical characteristics of 43 COVID-19 patients in Weifang, China
  117. Bioinformatic and biochemical findings disclosed anti-hepatic steatosis mechanism of calycosin
  118. SIRT1 agonism modulates cardiac NLRP3 inflammasome through pyruvate dehydrogenase during ischemia and reperfusion
  119. Novel insight into perirenal adipose tissue: A neglected adipose depot linking cardiovascular and chronic kidney disease
  120. Decreased shedding dipeptidyl peptidase 4 from membrane in Hashimoto's thyroiditis
  121. Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice
  122. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway
  123. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
  124. Identification of Potential Indicators for Survival in Patients with Thyroid Cancer Based on mRNA Expression Levels of Family with Sequence Similarity 3 Members
  125. Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice
  126. A Meta-Analysis of Pregnancy Outcomes with Levothyroxine Treatment in Euthyroid Women with Thyroid Autoimmunity
  127. AMPK: a balancer of the renin–angiotensin system
  128. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
  129. AMPK: a therapeutic target of heart failure—not only metabolism regulation
  130. Screening of differentially expressed proteins from syncytiotrophoblast for severe early-onset preeclampsia in women with gestational diabetes mellitus using tandem mass tag quantitative proteomics
  131. Calycosin directly improves perivascular adipose tissue dysfunction by upregulating the adiponectin/AMPK/eNOS pathway in obese mice
  132. C1q/TNF-related protein 9 improves the anti-contractile effects of perivascular adipose tissue via the AMPK-eNOS pathway in diet-induced obese mice
  133. Irisin Improves Endothelial Dysfunction through Perivascular Adipose Tissue
  134. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice
  135. Irisin improves endothelial function in obese mice through the AMPK-eNOS pathway
  136. Renal protective effects of induction of haem oxygenase-1 combined with increased adiponectin on the glomerular vascular endothelial growth factor-nitric oxide axis in obese rats
  137. Induction of Haemeoxygenase-1 Directly Improves Endothelial Function in Isolated Aortas from Obese Rats through the Ampk-Pi3k/Akt-Enos Pathway
  138. Induction of Haemeoxygenase-1 Improves FFA-Induced Endothelial Dysfunction in Rat Aorta
  139. The relationship between circulating irisin levels and endothelial function in lean and obese subjects
  140. Protective effects of adiponectin on uncoupling of glomerular VEGF–NO axis in early streptozotocin-induced type 2 diabetic rats
  141. Perirenal fat associated with microalbuminuria in obese rats
  142. Effect of high free fatty acids on the anti-contractile response of perivascular adipose tissue in rat aorta
  143. High FFA levels related to microalbuminuria and uncoupling of VEGF-NO axis in obese rats
  144. Sonographic evaluation of para- and perirenal fat thickness is an independent predictor of early kidney damage in obese patients
  145. The effect of telomerase activity on vascular smooth muscle cell proliferation in type 2 diabetes in vivo and in vitro
  146. Serum Fetuin-A Levels Related with Microalbuminuria in Diet-Induced Obese Rats
  147. Time–Action Profile of an Oral Enteric Insulin Formulation in Healthy Chinese Volunteers
  148. Correlation of ultrasonographic measurement of intrarenal arterial resistance index with microalbuminuria in nonhypertensive, nondiabetic obese patients
  149. Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats
  150. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK–eNOS pathways
  151. High free fatty acids level related with cardiac dysfunction in obese rats
  152. Effect of Aspirin on the Expression of Hepatocyte NF-κB and Serum TNF-α in Streptozotocin-Induced Type 2 Diabetic Rats
  153. Effect of polysaccharides of theEuphoria longan(Lour.) Steud on inflammatory response induced by focal cerebral ischemia/reperfusion injury in rats